鼻渊通窍颗粒联合曲安奈德鼻喷雾剂对比曲安奈德鼻喷雾剂治疗慢性鼻-鼻窦炎疗效和安全性的Meta分析和试验序贯分析
x

请在关注微信后,向客服人员索取文件

篇名: 鼻渊通窍颗粒联合曲安奈德鼻喷雾剂对比曲安奈德鼻喷雾剂治疗慢性鼻-鼻窦炎疗效和安全性的Meta分析和试验序贯分析
TITLE:
摘要: 目的:系统评价鼻渊通窍颗粒联合曲安奈德鼻喷雾剂治疗慢性鼻-鼻窦炎的临床疗效和安全性,为临床治疗提供循证参考。方法:计算机检索Embase、PubMed、Cochrane图书馆、中国知网、中国生物医学文献数据库、维普网、万方数据等,检索时限均为建库起至2018年12月8日,收集鼻渊通窍颗粒联合曲安奈德鼻喷雾剂(试验组)对比曲安奈德鼻喷雾剂(对照组)治疗慢性鼻-鼻窦炎的随机对照试验(RCT),对符合纳入标准的文献进行资料提取,并采用Cochrane偏倚风险评估工具5.1.0进行质量评价后,采用Rev Man 5.3软件对临床总有效率、鼻黏膜纤毛传输速率(MTR)、鼻腔分泌物中白细胞介素5(IL-5)和IL-8水平、鼻腔鼻窦结局测试-20(SNOT-20)评分、视觉模拟(VAS)评分、Lund-Mackey鼻窦CT评分和不良反应(恶心、皮疹)发生率等指标进行Meta分析,采用TSA 0.9软件进行试验序贯分析。结果:共纳入9项RCT,合计998例患者。Meta分析结果显示,试验组患者临床总有效率[RR=1.20,95%CI(1.14,1.26),P<0.001]显著高于对照组,MTR[MD=-231.74,95%CI(-291.89,-171.58),P<0.001]、 IL-5[MD=-0.86,95%CI(-1.37,-0.35),P<0.001]、IL-8[MD=-0.50,95%CI(-0.76,-0.25),P<0.001]水平均显著低于对照组,SNOT-20评分、视觉模拟(VAS)评分、Lund-Mackey鼻窦CT评分均低于对照组,差异均有统计学意义(P<0.001);两组患者恶心[RR=0.57,95%CI(0.17,1.92),P=0.37]、皮疹[RR=2.25,95%CI(0.70,7.20),P=0.17]发生率比较,差异均无统计学意义。试验序贯分析提示,鼻渊通窍颗粒联合曲安奈德鼻喷雾剂治疗慢性鼻-鼻窦炎的疗效证据确切。结论:鼻渊通窍颗粒联合曲安奈德鼻喷雾剂治疗慢性鼻-鼻窦炎在提高患者临床总有效率,降低MTR、IL-5、IL-8水平,改善SNOT-20评分、VAS评分、Lund-Mackey鼻窦CT评分方面优于单用曲安奈德鼻喷雾剂,且未增加恶心和皮疹的发生率。
ABSTRACT: OBJECTIVE: To systematically evaluate clinical efficacy and safety of Biyuan tongqiao granules combined with Triamcinolone acetonide nasal spray in the treatment of chronic rhinosinusitis, and to provide evidence-based reference for clinical treatment. METHODS: Retrieved from Embase, PubMed, the Cochrane library, CNKI, CBM, VIP and Wanfang database, RCTs about Biyuan tongqiao granules combined with Triamcinolone acetonide nasal spray (trial group) versus Triamcinolone acetonide nasal spray (control group) in the treatment of chronic rhinosinusitis were collected during database establishment to Dec. 8th, 2018. After data extraction and quality evaluation with Cochrane bias risk evaluation tool 5.1.0, Meta-analysis was performed for total response rate, nasal mucociliary transmission rate (MTR), the levels of IL-5 and IL-8 in nasal secretion, SNOT-20 score, VAS score, Lund-Mackey nasal sinus CT score, the incidence of ADR (nausea, rash) by using Rev Man 5.3 software. TSA 0.9 software was used for trial sequential analysis(TSA). RESULTS: A total of 9 RCTs were included, involving 998 patients. Results of Meta-analysis showed that total clinical response rate [RR=1.20,95%CI(1.14,1.26),P<0.001] of trial group was significantly higher than that of control group; MTR [MD=-231.74,95%CI(-291.89,-171.58),P<0.001], IL-5 [MD=-0.86,95%CI(-1.37, -0.35),P<0.001] and IL-8 [MD=-0.50,95%CI(-0.76, -0.25),P<0.001] levels of trial group were significantly lower than those of control group. SNOT-20 score, VAS score and Lund-Mackey nasal sinus CT score of trial group were all lower than those of control group, with statistical significance (P<0.001). There was no statistical significance in the incidence of nausea [RR=0.57,95%CI(0.17,1.92),P=0.37] or rash [RR=2.25,95%CI(0.70,7.20),P=0.17] between 2 groups. TSA analysis showed that the evidence for therapeutic efficacy of Biyuan tongqiao granules combined with Triamcinolone acetonide nasal spray in the treatment of chronic rhinosinusitis was reliable. CONCLUSIONS: Biyuan tongqiao granules combined with Triamcinolone acetonide nasal spray is better than Triamcinolone acetonide nasal spray alone in improving total response rate of Biyuan tongqiao granules combined with Triamcinolone acetonide nasal spray in the treatment of chronic rhinosinusitis, reducing MTR, the levels of IL-5 and IL-8, and improving SNOT-20 score, VAS score and Lund-Mackey nasal sinus CT score, without increasing the incidence of nausea, rash.
期刊: 2019年第30卷第11期
作者: 魏振鋆,习元堂,袁丽宜,徐思婷,邱宝珊
AUTHORS: WEI Zhenyun,XI Yuantang,YUAN Liyi,XU Siting,QIU Baoshan
关键字: 鼻渊通窍颗粒;曲安奈德鼻喷雾剂;慢性鼻-鼻窦炎;Meta分析;试验序贯分析
KEYWORDS: Biyuan tongqiao granules; Triamcinolone acetonide nasal spray; Chronic rhinosinusitis; Meta-analysis; Trial sequential analysis
阅读数: 572 次
本月下载数: 6 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!